Pulmonary Arterial Hypertension - Pharma

Relevant Publications

Pulmonary Complications of Portal Hypertension.

Issue Release: 2024

Quantification of treprostinil concentration in rat and human using a novel validated and rapid liquid chromatography-tandem mass spectrometry method: Experimental and clinical applications in ischemia-reperfusion injury.

Issue Release: 2024

Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross-sectional scientific survey (CLARITY).

Issue Release: 2024

Intraoperative hemodialysis with supra- and infradiaphragmatic catheters for liver transplantation.

Issue Release: 2024

C-type natriuretic peptide/cGMP/FoxO3 signaling attenuates hyperproliferation of pericytes from patients with pulmonary arterial hypertension.

Issue Release: 2024

Transcriptomic profiling highlights cell proliferation in the progression of experimental pulmonary hypertension in rats.

Issue Release: 2024

Pulmonary arterial hypertension associated with pretricuspid shunts: risk profile and survival.

Issue Release: 2024

A rare case of a simultaneous post-dissection saccular aneurysm of the ascending aorta and large pulmonary artery aneurysm with secondary embolism: a case report.

Issue Release: 2024

Management of pulmonary vascular disease associated with congenital left-to-right shunts: A single-center experience.

Issue Release: 2024

Fluorinated perhexiline derivative attenuates vascular proliferation in pulmonary arterial hypertension smooth muscle cells.

Issue Release: 2024

Sotatercept: First Approval.

Issue Release: 2024

Late-age onset systemic sclerosis-clinical and serological characteristics.

Issue Release: 2024

The association of right ventricular-pulmonary arterial coupling and pulmonary vascular resistance in adult patients with uncorrected atrial septal defect.

Issue Release: 2024

Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe.

Issue Release: 2024

The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases.

Issue Release: 2024

Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities.

Issue Release: 2024

miR-221-3p is upregulated in acute pulmonary embolism complicated with pulmonary hypertension and promotes pulmonary arterial smooth muscle cells proliferation and migration by inhibiting PTEN.

Issue Release: 2024

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.

Issue Release: 2024

Feasibility of Treat and Repair Strategy in Congenital Heart Defects With Pulmonary Arterial Hypertension.

Issue Release: 2024

Unraveling the Impact of miR-146a in Pulmonary Arterial Hypertension Pathophysiology and Right Ventricular Function.

Issue Release: 2024

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

What Roles Do Pharmacists Play in Pharma?

What is the Future of ADE Management?

What are the Benefits of Collaborative Care Models?

What is Pharma?

What Are the Challenges in Managing Chronic Conditions?

What is Cellular Stress?

What Role Does Regulatory Affairs Play?

What Challenges Exist in Patient Education?

Why are Collaborative Care Models Important in Pharma?

Pulmonary Arterial Hypertension - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics